USP22 orchestrates an NK-suppressive program for tumor immune evasion 2309931
This study identifies USP22 as a tumor-intrinsic suppressor of NK- and CD8+ T-cell—mediated antitumor immunity and reports a USP22-specific inhibitor with dual onco-targeting and immune-boosting activity, representing a first-in-class therapeutic strategy.